Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
✅️Elite Pharma (ELTP) Catalyst :✅️ UPDATE
Potential Catalysts by June 30th/July 1st in RED
✅️ 1. Cash Flow Positive
✅️ 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
✅️ 3. Adderall IR $421.7 Million IMS market Approved and Launched
✅️ 4. Adderall XR $865 Million IMS market Approved and Launched
✅️ 5. Double digit quarterly revenues in millions
✅️ 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
✅️ 7. DEA increases manufacturing quotas for Adderall & Vyvance
✅️ 8. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
✅️ 9. Generic Vyvanse - $4.3 BILLION - FDA submission Dec 2023
✅️ 10. FDA Acceptance of Generic OxyContin Sept 2023
✅️ 11. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__12. Obtain Full ownership of Adderall IR $ 421.7 Million from MIKAH
__13. Obtain Full ownership of Adderall XR $ 865 Million from MIKAH
✅️ 14. Generic Methotrexate Antimetabolite- Approval
✅️ 15. Launch generic Methotrexate $63 Million
✅️ 16. $50+ million in yearly revenues
✅️ 17. Lowest PE ratio for OTC Healthcare sector
✅️ 18. Become the ONLY company showing rapid growth on the OTC while being profitable
✅️ 19. Put Opioids back on the Table- due to reduced risk of opioid litigation
✅️ 20. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
✅️ 21. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
✅️ 22. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024
✅️ 23. Final Approval of New Manufacturing Facility/Expansion
__ 24. Generate revenues over $20 million/quarter —- Imminent
__ 25. Generate revenues over $30 million/quarter
__ 26. Generate revenues over $40 million/quarter
__ 27. Generate revenues over $50 million/quarter
__ 28. Double output of manufacturing and packaging facilities —-Imminent
✅️ 29. Launch approved generic Tylenol with Codeine $47 Million
✅️ 30. Launch approved generic Norco - hydrocodone acetaminophen IMS $300 Million
✅️ 31. Launch approved generic Percocet - oxycodone acetaminophen IMS $317 Million
__ 32. Launch approved generic Dolophine - Methadone HCL tablets IMS $30 Million
__ 33. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
✅️ 34. Generic Vyvanse (The Golden Goose) Approval $4.3 Billion
__ 35. Indian Research and Development agreement
__ 36. Positive BE Study for Concerta CNS Stimulant $1.16 Billion
✅️ ✅️ ✅️ 37. LAUNCH $4.3 Billion Generic Vyvanse Dec 2024
__38. Generic Concerta- FDA submission $1.16 Billion
__39. Launch Adderall IR in Israel —Imminent
__40. 100 million in yearly revenues —-2025
__41. Generic OxyContin Approval $720 Million
✅️ 42. Accord prevail over Purdue in Generic OxyContin infringement suit - Dec 30, 2024
https://cafc.uscourts.gov/opinions-orders/23-1953.OPINION.12-30-2024_2443222.pdf
__43. Elite prevail over Purdue in Generic OxyContin infringement suit.
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
__43. Launch generic OxyContin $720 Million
__44. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone
__45. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__46. $200 million in yearly revenue
__47. Patented NDA Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__48. Undisclosed Mikah ANDA(s)
X. 49. Positive Pivotal BE Undisclosed ANDA JUNE 2025 $27 Billion Market anticoagulant
__50. Generic Concerta Launch $1.16 Billion
__51. DollarLand PPS ——2025
__52. Uplist to NASDAQ exchange
__53. M&A advisory firm selected for buyout
__54. Perform Business Valuation
__55. Develop strategy set for sale of business
__56. Prepare marketing materials for sale
__57. The advisory firm begins to identify and approach potential buyers.
__58. Management teams present the company's strengths and growth potential to interested buyers
__59. Site visits by potential Buyers to inspect and meet management.
__60. Begin Buyout Negotiations
__61. Buyout offer/s
__62. Buyer Identified
__63. Purchase Definitive Agreement
__64. Buyout Vote of Board of Directors
__65. Halt Trading
__66. Shareholder vote on offer
__67. Necessary regulatory approvals are obtained for transfer of ownership
__68. Buyout Closing Completed —$$$$$$$$$$$
__69. Vegas BABY !!!!! 🎰
LOL Really?
translates your guesses to annual figures as we will not see the Q4 numbers i
Sub 12. Message board rumors are dying out. There's no buyout, uplisting, mergers. Pure fabrication and feces. Don't drink the Kool aide. Bridges are almost done. Another otc play unfolding.
....also the national debt clock
Pre Markey Trades and Valid Recon is all we should be discussing.
NASDAQ2020 can you please post the Clock countdown and the List of catalysts with the ones at risk of being met next week in a different color?
ELTP Investors.
I am watching this board and the guesses you all post, and I must say that if we indeed report around these numbers, this will be a 200% growth quarter over quarter and that would be amazing!!!
I would recommend though that the fake King translates your guesses to annual figures as we will not see the Q4 numbers in the PR that we will get on June 30th.
Please add $52,083,000 to the Q4 figure you posted.
Thanks
Lol again sorry dictation ......of course it was supposed to say the guessing not the guest game!
Wow: The guest, the quarter game has rapidly gained some attention here. I remember when there was only about eight of us doing it, but this is very good and it's gonna be very good for all of us. Congratulations on having the interest and the due diligence to invest in this life changing opportunity with Elite pharmaceutical. 😎 No Brag, Just Fact!
Just remember kool aide drinkers. There's no buyout, no uplisting, no mergers. Those were silly message board rumors to get you to be exit liquidity. I got bridges going thru inspection they will be ready on/near July 1st. Here's all you need to know.
https://www.reddit.com/r/wallstreetbets/comments/1l7a5hj/my_1_million_investment_triple_up_is_about_to/
✔️ Zero liquidity
As previously stated, the Revenue Guessing Game (which I invented), began TODAY.
Therefore, HERE is my guess: 31,840,762
And HERE are the other guesses (so far) today:
snupoled - 22,750,000
Toasted_oats - 23,500,000
topki - 26,700,000
kennyt 335 - 27,111,196
jdd21 - 28,700,000
rdfdr1 - 29,200,000
BZ2 - 29,450,000
ubueltp - 29,777,777
Rj70 - 32,750,000
rocioyogi - 33,200,000
ThePoorTeacher - 34,971,411
Nothing.
Standard operating procedure.
So what’s up with this new 8k
Her name is Dianne.
That's reason for a legitimate call to Diane
Elite doesn't control the calendar of 90 days for the 10-K and 45 days for the 10-Q.
Good grief...
Release on a Monday and CC on a Tuesday.................... Definitely not trying to bury anything
Loser!
I had just sold 8000 shares
Pretending as if you're new to Elite and didn't already know that the info is listed in the press release...
Whats the email address to send questions? I have several
Are you new to Elite?
They ALWAYS wait the MAX time to file the 10-K/10-Q.
They don't file it on certain days whether the news is good or bad.
We've had financials released on EVERY day of the week.
Elite doesn't control the calendar.
Good grief...
Good sign that it’s on a Monday and Tuesday Not a Friday when you hide bad news
As if I haven't been telling everyone the dates for over a month...
CC next Tuesday. Email fired off. Earnings release on Monday.
DAM you're good.
You've been telling everyone these dates for OVER a month!
June 30: 10-K filed after hours 📄
July 1: Conference call with pop🥤and popcorn 🍿
I was thinking Tuesday with questions due Friday.
They always make us wait. Im thinking Thursday or Friday.
How's the saying go? Golden showers lead to explosive ELTP power hours? 🤔
✅️Elite Pharma (ELTP) Catalyst :✅️ UPDATE
✅️ 1. Cash Flow Positive
✅️ 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
✅️ 3. Adderall IR $421.7 Million IMS market Approved and Launched
✅️ 4. Adderall XR $865 Million IMS market Approved and Launched
✅️ 5. Double digit quarterly revenues in millions
✅️ 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
✅️ 7. DEA increases manufacturing quotas for Adderall & Vyvance
✅️ 8. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
✅️ 9. Generic Vyvanse - $4.3 BILLION - FDA submission Dec 2023
✅️ 10. FDA Acceptance of Generic OxyContin Sept 2023
✅️ 11. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__12. Obtain Full ownership of Adderall IR $ 421.7 Million from MIKAH
__13. Obtain Full ownership of Adderall XR $ 865 Million from MIKAH
✅️ 14. Generic Methotrexate Antimetabolite- Approval
✅️ 15. Launch generic Methotrexate $63 Million
✅️ 16. $50+ million in yearly revenues
✅️ 17. Lowest PE ratio for OTC Healthcare sector
✅️ 18. Become the ONLY company showing rapid growth on the OTC while being profitable
✅️ 19. Put Opioids back on the Table- due to reduced risk of opioid litigation
✅️ 20. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
✅️ 21. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
✅️ 22. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024
✅️ 23. Final Approval of New Manufacturing Facility/Expansion
__ 24. Generate revenues over $20 million/quarter —- Imminent
__ 25. Generate revenues over $30 million/quarter
__ 26. Generate revenues over $40 million/quarter
__ 27. Generate revenues over $50 million/quarter
__ 28. Double output of manufacturing and packaging facilities —-Imminent
✅️ 29. Launch approved generic Tylenol with Codeine $47 Million
✅️ 30. Launch approved generic Norco - hydrocodone acetaminophen IMS $300 Million
✅️ 31. Launch approved generic Percocet - oxycodone acetaminophen IMS $317 Million
__ 32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
__ 33. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
✅️ 34. Generic Vyvanse (The Golden Goose) Approval $4.3 Billion
__ 35. Indian Research and Development agreement
__ 36. Positive BE Study for Concerta CNS Stimulant $1.16 Billion
✅️ ✅️ ✅️ 37. LAUNCH $4.3 Billion Generic Vyvanse Dec 2024
__38. Generic Concerta- FDA submission $1.16 Billion
__39. Launch Adderall IR in Israel —Imminent
__40. 100 million in yearly revenues —-2025
__41. Generic OxyContin Approval $720 Million
✅️ 42. Accord prevail over Purdue in Generic OxyContin infringement suit - Dec 30, 2024
https://cafc.uscourts.gov/opinions-orders/23-1953.OPINION.12-30-2024_2443222.pdf
__43. Elite prevail over Purdue in Generic OxyContin infringement suit.
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
__43. Launch generic OxyContin $720 Million
__44. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone
__45. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__46. $200 million in yearly revenue
__47. Patented NDA Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__48. Undisclosed Mikah ANDA(s)
X. 49. Positive Pivotal BE Undisclosed ANDA JUNE 2025 $27 Billion Market anticoagulant
__50. Generic Concerta Launch $1.16 Billion
__51. DollarLand PPS ——2025
__52. Uplist to NASDAQ exchange
__53. M&A advisory firm selected for buyout
__54. Perform Business Valuation
__55. Develop strategy set for sale of business
__56. Prepare marketing materials for sale
__57. The advisory firm begins to identify and approach potential buyers.
__58. Management teams present the company's strengths and growth potential to interested buyers
__59. Site visits by potential Buyers to inspect and meet management.
__60. Begin Buyout Negotiations
__61. Buyout offer/s
__62. Buyer Identified
__63. Purchase Definitive Agreement
__64. Buyout Vote of Board of Directors
__65. Halt Trading
__66. Shareholder vote on offer
__67. Necessary regulatory approvals are obtained for transfer of ownership
__68. Buyout Closing Completed —$$$$$$$$$$$
__69. Vegas BABY !!!!! 🎰
Bullish
BULLISH
Don't worry your destiny will be defined. Sub 12. You're exit liquidity. No buyout, no mergers, no nothing. Just rumors on message boards. Otc fantasy world in full force. Don't cry, have some of your urine flavored Kool aide. I hear you like that all over your face too. No bridge for you.
Good news, Henry. Your favorite flavor is back in stock at your local grocery store!
Koolaide for everyone. 8 new flavors
Henry’s estimate for the quarter is 12 cents
Followers
|
1140
|
Posters
|
|
Posts (Today)
|
26
|
Posts (Total)
|
429373
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators Dr Speculator Ninja mrwrn2010 NASDAQ2020 namtae |
Senior Moderator: NASDAQ2020
Posted: 7/02/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 64 | 85,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 421.7 M | On Market | 16 | Elite, Dexcel |
Adderall XR | 865 M | On Market | 10 | Elite |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 47 M | On Market | 5 | Elite |
Dopamine Agonist | 12 M | Filed with FDA - Dec 22, 2022 | ---------- | ---------- |
Methotrexate | 63 M | On Market | 8 | Elite |
Percocet | 317 M | On Market | 14 | Elite |
Norco | 300 M | On Market | 12 | Elite |
Methadone | 30 M | Approved in Launch Queue | 8 | ---------- |
OxyContin | 720 M | Filed with FDA - Aug 17, 2023 | 4 | ---------- |
Vyvanse | 4.3 B | On Market | 13 | Elite |
Concerta | 1.16 B | BE Studies | 8 | ---------- |
Undisclosed ANDA | 27 B | Positive BE Study | 1 | ----------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 | 56,625,128 | +65.79% | 20,108,631 | +464.56% |
2025 Q-1 | 18,803,000 | +109.39% | 3,864,056 | +144.00% |
2025 Q-2 | 18,880,000 | +33.00% | 3,500,000 | +84.00% |
2025 Q-3 | 14,400,000* | -8.00% | 1,100,000 | -69.00% |
2025 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |